Key result
In-stent restenosis for drug-eluting stents now surpasses 10% of total percutaneous coronary interventions in the United States, presenting a persistent management challenge.
Why the study?
Does off-label use of peripheral drug-coated balloons effectively treat coronary drug-eluting stent in-stent restenosis?
Does off-label use of peripheral drug-coated balloons effectively treat coronary drug-eluting stent in-stent restenosis?
Managing DES-ISR remains a significant challenge, with off-label use of peripheral drug-coated balloons being discussed as a potential remedy.
The reported annual rate of in-stent restenosis (ISR) for drug-eluting stents (DES) in the United States now surpasses 10% of total percutaneous coronary interventions (PCI) despite advances in DES technology.1 Managing DES-ISR continues to present a significant challenge, and the search for an effective remedy for this phenomenon persists.
No takes yet. Share an insight, caveat, or question.
Waksman et al. (2024) studied this question. In-stent restenosis for drug-eluting stents now surpasses 10% of total percutaneous coronary interventions in the United States, presenting a persistent management challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: